PharmEng International Inc.
TSX VENTURE : PII

PharmEng International Inc.

August 09, 2007 13:21 ET

PharmEng Names David G. Leonard as President Keata Pharma

TORONTO, ONTARIO--(Marketwire - Aug. 9, 2007) - PharmEng International Inc. ("PharmEng") (TSX VENTURE:PII), a full-service consulting and contract manufacturing company, is pleased to announce that David G. Leonard is appointed the Keata Pharma President for the Sydney and Perth manufacturing sites. David will succeed Bernie Boudreau who will assume the new role as the Vice President of Corporate Development and Legal Affairs of PharmEng. Keata Pharma is a wholly owned subsidiary of ParmEng with manufacturing facilities in Perth, Ontario and new facilities in Sydney, Nova Scotia scheduled to open in the fourth quarter of this year.

David has held numerous senior roles in the manufacturing sector from large multinationals to medium and small privately owned companies. Prior to joining PharmEng, David held key operations and business development positions with another contract manufacturing company. David obtained his undergraduate engineering degree from Lakehead University, an MBA from Queen's School of Business and is a member in good standing with the Professional Engineers of Ontario and the Certified Management Accountants of Ontario.

"PharmEng is fortunate to have David as part of the executive team with the main responsibility to advance the contract manufacturing business for Keata Pharma", said Alan Kwong, CEO of PharmEng International Inc.

About PharmEng International Inc.

PharmEng International Inc., headquartered in Toronto, Canada, is a full-service consulting and contract manufacturing company that serves the pharmaceutical and biotechnology industries in North America and internationally. Consulting services include project management, engineering, GMP, validation, calibration, regulatory compliance and certified training. Contract manufacturing includes pharmaceutical support, formulation development, laboratory testing, and finished solid dosage and liquid products. PharmEng's shares trade on the TSX Venture Exchange under the symbol PII. For more information about PharmEng, please visit the Company's website at www.pharmeng.com.

FORWARD LOOKING STATEMENTS

Certain statements in this press release may include "forward-looking" statements which involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements of PharmEng to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. When used in this press release, such statements use such words as "may", "will", "expect", "anticipate", "project", "believe", "plan", and other similar terminology. The risks and uncertainties are detailed from time to time in reports filed by PharmEng with the securities regulatory authorities in all of the provinces and territories of Canada. New risk factors may arise from time to time and it is not possible for management to predict all of those risk factors or the extent to which any factor or combination of factors may cause actual results, performance and achievements of PharmEng to be materially different from those contained in forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction actual results.

Contact Information

  • PharmEng International Inc.
    Bert Loveless
    Chief Financial Officer
    (905) 415-3922 x 107
    Website: www.pharmeng.com